Acute Hereditary Angioedema Products: Berinert, Kalbitor, and Ruconest
Customize your policy alerts
Sign up for marylandphysicianscarempc Policy RX.PA.001.MPC alerts
Get alerted when Policy RX.PA.001.MPC changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization, coverage criteria, and renewal requirements for Berinert, Kalbitor, and Ruconest for treatment of acute hereditary angioedema (HAE) attacks for Maryland Physicians Care members and providers.
No material clinical or coverage changes in this revision.
Coverage Criteria for Acute HAE Products
Initial Authorization
Covered when ALL of the following are met:
Prescriber requirement
- Must be prescribed by or under the direction of an HAE specialist (defined as an allergist/immunologist who demonstrates clinical expertise in HAE through research, publication, referrals/consults).
Diagnostic confirmation
- Diagnosis of HAE confirmed by ALL of the following laboratory values on two separate instances (copy of laboratory reports required; must include reference ranges): low C4 complement level.
- Normal C1q complement component level (C1q not required for patients <18 years or whose symptoms began before age 18).
AND either of the following
- Low C1 esterase inhibitor antigenic level.
- Low C1 esterase inhibitor functional level.
Age requirements (product-specific)
- Berinert: member is 2 years of age or older.
- Kalbitor: member is 12 years of age or older.
- Ruconest: member is 13 years of age or older.
Reauthorization
Covered when ALL of the following are met:
Authorizations may be extended at 1-year intervals.
Not covered / investigational uses
Any use of the listed acute hereditary angioedema (HAE) products outside of treatment for acute HAE attacks is considered investigational/experimental and is not covered.
Billing and Coding
Provider Actions, Documentation, and Denial Triggers
Prior authorization required; initial limit 1 fill and annual reauthorization
Prior authorization is required for Berinert, Kalbitor, and Ruconest; initial approvals must meet all listed initial authorization criteria and are limited to 1 fill. Reauthorizations are reviewed annually and may be extended at 1-year intervals with prescriber documentation of improvement.
- Initial Authorization limited to 1 fill.
- Reauthorization reviewed on an annual basis; may be extended at 1-year intervals.
Dosing must follow FDA‑approved manufacturer labeling
Prescribed dose must follow the manufacturer's dosing guidelines as listed in the FDA‑approved labeling (dose determined by diagnosis, weight, etc.).
- Dose must be within manufacturer's dosing guidelines per FDA labeling.
Required documentation: labs, chart notes, and prescriber assessment
Providers must submit objective laboratory confirmation and chart evidence: copies of lab reports (including reference ranges) showing required diagnostic labs on two separate occasions, and chart documentation of prior receipt of at least one dose with response and tolerability; for renewals, documentation from the prescriber that the member's condition has improved.
- Copy of laboratory reports (must include reference ranges) documenting on two separate instances: low C4; normal C1q (not required if patient <18 or symptoms began <18); and either low C1 esterase inhibitor antigenic level OR low C1 esterase inhibitor functional level.
- Chart documentation that the member received at least one prior dose of the requested product for an acute HAE attack with documented response and tolerability.
- For reauthorization: prescriber documentation that the member's condition has improved while on therapy.
- Members with prior approval from another insurer or receiving samples must be evaluated under Initial Authorization criteria with documentation of positive clinical response from baseline.
Denial triggers and Medical Director referral for unmet criteria
Requests will be denied or referred to a Medical Director when the established criteria are not met; note limits include an initial authorization of 1 fill and reauthorization of up to 1 year which may be denied if criteria are not satisfied.
- Denial trigger: failure to meet all Initial Authorization criteria (including diagnostic labs, specialist prescriber, prior dose with documented response, age requirements, and appropriate dosing).
- Non‑covered/investigational use: any use other than treatment of acute HAE attacks is excluded from coverage.
- Requests not meeting criteria may be referred to a Medical Director for review as required by the plan and level of request.
Background
Hereditary angioedema (HAE) is a rare disorder characterized by recurrent swelling attacks caused by deficiency or dysfunction of C1 esterase inhibitor. This policy applies to acute HAE treatment products — Berinert (human C1 esterase inhibitor), Kalbitor (ecallantide), and Ruconest (recombinant C1 esterase inhibitor) — and defines prior authorization, coverage criteria, and renewal requirements for their use in treating acute attacks.
Coverage is limited to members who meet diagnostic confirmation requirements and other criteria in the policy (for example, laboratory confirmation on two separate occasions, prescriber expertise, prior receipt of the requested product with documented response, and age-specific product indications).
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.